Featured Publications
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity
2011
Serotype replacement in disease after pneumococcal vaccination
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. The Lancet 2011, 378: 1962-1973. PMID: 21492929, PMCID: PMC3256741, DOI: 10.1016/s0140-6736(10)62225-8.Peer-Reviewed Original ResearchConceptsNon-vaccine serotypesSerotype replacementPneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePneumococcal conjugate vaccineImportant public health benefitsBenefits of vaccinationPublic health benefitsDisease surveillance systemsNVT carriagePneumococcal vaccinationSurveillance biasesConjugate vaccineVaccine serotypesCarriage prevalencePneumococcal serotypesAsymptomatic carriersCarriage dataDiseaseVaccinationHealth benefitsLow invasivenessPrevalenceSerotypesCarriage
2009
Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence
Weinberger DM, Trzciński K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence. PLOS Pathogens 2009, 5: e1000476. PMID: 19521509, PMCID: PMC2689349, DOI: 10.1371/journal.ppat.1000476.Peer-Reviewed Original ResearchConceptsSerotype replacementCarriage prevalenceNasopharyngeal carriageCapsular serotypesNon-vaccine serotypesNeutrophil-mediated killingNasopharyngeal carriage prevalenceCapsular polysaccharideVaccinated populationSerotype prevalenceEpidemiological patternsPrevalent serotypesStreptococcus pneumoniaeBacterial factorsParticular serotypePrevalenceImportant serotypesNovel biological principleSerotypesDifferent serotypesCarriageNeutrophilsBiological differencesKillingVaccination